Smith+Nephew agrees to $240M deal to acquire Integra LifeSciences' extremity orthopedics line

Alan Condon -   Print  | Email

Smith+Nephew on Sept. 29 agreed to acquire the extremity orthopedics business from Integra LifeSciences for $240 million in cash.

The business unit includes ankle and shoulder arthroplasty as well as hand and wrist products. It posted $90 million in 2019 revenue and about $32.7 million in revenue during the first six months of 2020.

Smith+Nephew will expand the "reach and scale" of the extremity orthopedics portfolio, said Integra LifeSciences President and CEO Peter Arduini.

Mr. Arduini sees the transaction as a way to bolster the company's neurosurgery, surgical instrumentation and regenerative medicine portfolios.

Integra LifeSciences plans to use the net proceeds of the sale for debt reduction and reinvestment in organic and inorganic opportunities.

The deal is expected to close by the end of 2020.

More articles on devices:
Dr. Mark Erickson performs 100th robotic-assisted pediatric spine surgery
6 spine surgeons on the biggest obstacle they face going forward
North American Spine Society recognizes 20 spine specialists under 40

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.